Pfizer announced top-line results from Oral Psoriatic Arthritis triaL (OPAL) Beyond, the second Phase III study of Xeljanz (tofacitinib citrate)...
Oral Psoriatic Arthritis TriaL (OPAL) studies, Broaden and Beyond, were presented at the 2016 ACR/ARHP Annual Meeting (November 11-16, Washington,...
Fluoride 2800 ppm Toothpaste is indicated in adolescents, and children aged 10 years and over. Prevention and treatment of dental caries (coronal and root) adolescents and children aged ten years or more.
Pfizer Inc. announced top-line results from its first Phase III study investigating tofacitinib for the treatment of psoriatic arthritis, Oral...
The EU Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms...
Fluoride 5000 ppm Toothpaste is indicated in adults and adolescents aged 16 years and over. Prevention of dental caries in adolescents and adults, particularly amongst patients at risk from multiple caries (coronal and / or root caries).
To examine the safety and efficacy of tofacitinib in subjects with active psoriatic arthritis who have previously had an inadequate response to at least one TNF inhibitor either due to lack of efficacy or an adverse event.
This is a Phase 3, long-term open-label extension study to evaluate the safety, tolerability and efficacy of tofacitinib in subjects with active PsA who have previously participated in randomized studies of tofacitinib for this indication.